1. Medtech Insight

Thermo Fisher Scientific Announces $11.5Bn Buyout Of Qiagen

 
• By Catherine Longworth and Reed Miller

Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.

M&A, Mergers and Acquisitions. US Dollar texture. - Illustration

Thermo Fisher Scientific Inc. is acquiring Dutch diagnostics firm Qiagen NV in a $11.5bn deal, the companies announced 3 March.

Thermo Fisher said it will acquire Qiagen for €39 per share in cash, representing a 23% premium to the closing price of Qiagen’s stock on 2 March.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business